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Background: Long-acting antipsychotic therapy may be best suited for patients in the early 
stage of schizophrenia, when the most can be done before disease progression associated with 
poor adherence occurs. We explored the patterns of use of once-monthly paliperidone palmitate 
(PP1M), concomitant medication use, hospitalization, and clinical outcomes of adult, newly 
diagnosed patients with schizophrenia receiving continuous treatment with PP1M for at least 
12 months.
Methods: This was an international, multicenter, exploratory, retrospective chart review of 
medical records of adult patients who were newly diagnosed (not more than 1 year before 
initiation of PP1M treatment) with schizophrenia and who had received continuous treatment 
with PP1M for $12 months in naturalistic clinical settings.
Results: A total of 84 (93.3%) patients were included in the analysis. All but one patient (98.8%, 
n=83) had received oral antipsychotic medication at least during the last month before the first 
PP1M administration. Three patients (3.6%) were newly hospitalized during the 12-month 
documentation period. The reason for hospitalization for all three was management of episode/
relapse. A total of 79.2% of patients had a $20% improvement and 47.2% had a $50% improve-
ment in Positive and Negative Syndrome Scale total score from baseline to endpoint. Half of 
patients (53.3%) showed a significant improvement, as reflected by an increase in Personal and 
Social Performance (PSP) total score of at least 7 points from baseline to endpoint (mean [SD] 
11.9 [15.0] points; P,0.001). One quarter of patients (24.4%, n=11) moved from a PSP score 
of 31–70 (ie, moderate to marked functional impairment) at baseline to a PSP score of mild 
to no functional impairment (PSP score $71) at endpoint. Most adverse drug reactions were 
mild or moderate in severity.
Conclusion: Continuous treatment with PP1M over 12 months was associated with statistically 
significant and clinically meaningful improvements in psychotic symptoms, disease severity, 
and functional outcomes in patients with schizophrenia.
Keywords: long-acting antipsychotic, early diagnosis, schizophrenia, paliperidone palmitate
Introduction
Schizophrenia is a chronic, progressive disease characterized by one or more psychotic 
episodes.1,2 A large proportion of patients with schizophrenia fail to achieve remis-
sion or to recover – at least to the same level as before the prior episode. The pro-
cess of relapse and incomplete remission often leads to the chronicity of the illness, 
which is associated with persistent symptoms and lasting deficits in functioning and 
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cognition.1 Patient response to antipsychotic medication is 
reduced as the illness progresses, and evidence suggests 
that relapse events are a critical factor in the emergence of 
treatment refractoriness.3,4 Although there are a number of 
factors that may contribute to an increased risk of relapse, 
treatment discontinuation is a very common and important 
factor in clinical settings, particularly in the early stages of 
the disease.3,5 However, if patients commit to treatment early 
in the course of the illness, there is a substantial reduction in 
number of relapses and a higher rate of remission of psychotic 
symptoms following the initial episode.1,4,6
Long-acting antipsychotic therapy (LAT) may help to 
effectively manage the disease in the critical early years by 
optimizing adherence, improving treatment response, reduc-
ing the risk of relapse, and improving long-term outcomes.7,8 
LATs already have an established role in the maintenance 
treatment of chronic, poorly adherent, and/or severely ill 
patients in the later stages of schizophrenia. However, LAT 
may perhaps be best suited for patients in the early stage of 
illness after an initial diagnosis of schizophrenia, when the 
most can be done for patients before disease progression 
associated with poor adherence occurs.7,8 Therefore, LATs 
should be considered as an early and even first-line option 
in treating schizophrenia, with some guidelines already 
reflecting this position.2,9 However, partly because of the 
paucity of evidence for the use of LATs early in the course 
of schizophrenia, these agents are not often recommended 
to this patient population.7
The comparative effectiveness of LAT and oral antipsy-
chotics may largely depend on study designs;10,11 although 
some recent randomized controlled trials have shown no 
major differences in efficacy, a large set of prospective, retro-
spective, and mirror-image observational studies conducted 
in more naturalistic and realistic settings have shown sig-
nificantly favorable outcomes.10,12–14 Here, we report the 
findings of an international, multicenter, non-interventional, 
retrospective chart review that explored the patterns of use of 
once-monthly paliperidone palmitate (PP1M), concomitant 
medication use, hospitalization, and clinical outcomes of 
adult, newly diagnosed patients with schizophrenia receiving 
continuous treatment with PP1M for at least 12 months in 
naturalistic clinical settings.
Methods
study design
This was an international, multicenter, exploratory, retrospec-
tive chart review of medical records of adult patients who 
were newly diagnosed (not more than 1 year before initia-
tion of PP1M treatment) with schizophrenia and who had 
received continuous treatment with PP1M for $12 months. 
The chart review was conducted at centers in Croatia, Italy, 
Russia, and Turkey, in which PP1M was approved and avail-
able. Our study was specifically designed to select a young 
patient population at a very early stage of schizophrenia. In 
accordance with the non-interventional, retrospective study 
design, patients did not receive any study-specific treatments 
or any study-specific assessments or evaluations in addition 
to the treatment they were prescribed by their treating physi-
cian. The retrospective documentation period started from the 
date of the first PP1M administration (baseline) and ended 
after the first 12 months (365±31 days) of continuous treat-
ment with PP1M (endpoint). Endpoint data were the latest 
data collected within the 12-month documentation period. 
Informed written consent was provided by all patients for ret-
rospective data collection and analysis. Ethics approval was 
provided by the appropriate institutions in the participating 
countries: Turkey (Pamukkale University Medical Faculty 
Non-Interventional Clinical Trials Ethics Committee), Italy 
(Comitato Etico dell’Azienda Sanitaria, dell’Alto Adige 
c/o Comprensorio, Sanitario di Bolzano, and Comitato 
Etico A.O. Universitaria Vittorio Emanuele II di Catania), 
Russia (Independent Ethics Committee at OOO “Arte 
Med Assistance”, Independent Ethics Committee at Sankt-
Peterburgskiy Nauchno-issledovatelskiy institut im. V.M. 
Bekhterev, and Local Ethics Committee at Gosudarstvennoye 
Kazennoye Uchrezhdeniye Zdravookhraneniya of Moscow 
Region “Tsentralnaya Klinicheskaya Psikhiatricheskaya 
Bolnitsa”), and Croatia (Central Ethics Committee, Zagreb).
Patient selection criteria
eligible patients
Patients aged 18–29 years at the time of first PP1M adminis-
tration, with a documented diagnosis of schizophrenia (either 
according to International Classification of Diseases [ICD]-10 
or to Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition [DSM-IV]) were included. First psychotic epi-
sode suggestive of schizophrenia must have been clinically 
evident not longer than 1 year before the first PP1M admin-
istration. Documentation of continuous treatment (defined as 
regular consecutive administration, as prescribed by the treat-
ing clinician, with not more than one missed administration 
within the 12-month documentation period) with PP1M for 
at least 12 months (365±31 days) administered for the first 
time as part of routine clinical practice was required.
Non-eligible patients
Patients with an ICD-10 or DSM-IV axis 1 diagnosis other 
than schizophrenia were excluded, along with patients 
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diagnosed with alcohol or drug dependence (except for 
nicotine and caffeine dependence) within 1 month before 
the initiation of PP1M treatment or during the 12-month 
documentation period. Patients treated with any LAT before 
PP1M initiation or with an LAT other than PP1M during the 
12-month documentation period were not eligible.
Outcome measures
Primary outcome
Hospitalization – encompassing the number of psychiatric 
hospitalizations, the number of psychiatric hospitaliza-
tion days, and the reasons for hospitalizations during the 
12-month documentation period.
Other outcomes of interest
Patterns of PP1M treatment within the 12-month documen-
tation period, treatment response (measures of clinical ill-
ness, symptom severity), psychosocial functioning, medical 
resource utilization, psychiatric hospitalizations during the 
year preceding the first PP1M administration, and safety 
results were as reported and documented by the clinicians 
in the medical records.
assessment of clinical and functional treatment 
response
The following measures were reported as they were available 
in the patient records.
Symptom severity – Positive and Negative Syndrome 
Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS): 
clinically relevant improvement, defined as a $20% decrease 
in mean PANSS or BPRS total score from baseline to end-
point; or Clinical Global Impression-(CGI) Severity (CGI-S) 
and/or CGI-Change (CGI-C): clinically relevant improve-
ment will be defined as an improvement in CGI-S of at least 2 
points from baseline to endpoint and/or a CGI-C score of #2 
(much or very much improved) at endpoint, and no PANSS, 
BPRS, CGI-S or CGI-C score indicating disease worsening; 
decrease in CGI-S score of #2 points or a CGI-C score of #3 
(1= very much improved; 2= much improved; 3= minimally 
improved) at endpoint and with no PANSS, BPRS, CGI-S 
or CGI-C score indicating disease worsening.
Functioning – Personal and Social Performance (PSP), 
Global Assessment of Functioning (GAF) or Social and 
Occupational Functioning Assessment Scale (SOFAS): 
clinically relevant functional improvement, defined as an 
increase in PSP total score of $7 points, or an increase in 
GAF total score of $20 points or an increase in SOFAS total 
score of $30% from baseline to endpoint and with no PSP, 
GAF, or SOFAS score indicating worsening of the disease.
Statistics
Descriptive statistics were used for all outcomes. Within-
group changes from baseline to endpoint were tested using 
the two-sided Wilcoxon signed-rank test with type I error 
fixed at 0.05. The last observation carried forward method 
was used for the endpoint in the analyses of clinical and 
functional response parameters.
Results
Demographics and baseline 
characteristics
A total of 90 patients provided written informed consent 
for this study; of these, 84 (93.3%) patients were eligible 
for analysis and were included in the full analysis set, and 
88 (97.8%) patients received at least one dose of PP1M 
and were included in the safety analysis set. Two thirds 
of the patients (69.0%) were male, and the mean age was 
24.1(SD 2.7), range 19–29 years. The mean (SD) age at first 
psychotic episode was 23.8(2.6) years and the mean (SD) 
time between first onset of psychotic symptoms and the first 
PP1M administration was 5.5(3.3) months (Table 1). All but 
one patient (98.8%, n=83) had received oral antipsychotic 
medication at least during the last month before the first 
PP1M administration.
PP1M dosing
Overall, 69.0% (n=58) of patients received PP1M accord-
ing to the initiation regimen as recommended in the sum-
mary of product characteristics (150 mg, Day 1; 100 mg, 
Day 8±4 days, both in deltoid muscle).15 The main reasons 
for PP1M initiation as documented by the treating clinician 
were relapse prevention (56.0%), partial/non-adherence to 
previous medication (20.2%), and convenience (15.5%). 
From Month 1 after first PP1M administration onwards, 
67.9% (n=57) of patients did not change their dose, 6.0% 
(n=5) of patients had a dose increase, and 28.6% (n=24) 
of patients had a dose decrease. Overall, 7.1% (n=6) of 
patients had a dose decrease because of tolerability reasons 
and 21.4% (n=18) of patients had a decrease to minimize 
exposure. However, efficacy and/or tolerability were within 
expectation according to the treating clinician.
switching and concomitant antipsychotics
A total of 90.5% (n=76/84) of patients were switched from a 
daily oral antipsychotic to PP1M. Most patients (77.4%, n=65) 
were switched to PP1M from antipsychotic monotherapy and 
13.1% (n=11) of patients were switched from antipsychotic 
polytherapy. The main antipsychotic from which patients 
were switched was risperidone (n=58 [69.0%]), followed 
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by paliperidone extended release (n=8 [9.5%]), and olan-
zapine (n=7 [8.3%]). In the 65 patients who switched from 
oral monotherapy, 17.9% (n=15) stopped their pre-switch 
antipsychotic the day before or at the day of the first PP1M 
administration: for 45.2% (n=38) of patients, the pre-switch 
anti psychotic monotherapy was tapered off within 4 weeks 
after the first dose of PP1M; 14.3% of patients (n=12) con-
tinued their pre-switch medication for .4 weeks. The most 
common antipsychotics used concomitantly with PP1M 
among the full analysis set during the documentation period 
were oral risperidone (45.2%), olanzapine (7.1%), clozapine 
(6.0%), and haloperidol (6.0%) (Table 1).
hospitalizations
Hospitalizations are summarized in Table 2. Of 84 patients 
in the full analysis set, three (3.6%) were newly hospitalized 
during the 12-month documentation period. The reason for 
hospitalization for all three was management of episode/
relapse; the mean number of hospitalization days was 
15.7 (mean of 10, 12 and 25) days (Figure 1).
None of the hospitalizations were reported to be a result of 
a serious adverse drug reaction (ADR). Almost half of patients 
(42.9%) were in hospital at the time they received the first 
PP1M administration (index hospitalizations – hospitalizations 
that started before the first PP1M administration and ended 
after the first PP1M administration), and the mean number of 
days spent in this index hospital stay (SD) was 52.1(40.6) days. 
The main reason for the index hospitalization was manage-
ment of episode/relapse with the previous oral antipsychotic 
medication (35 of 36 patients were receiving oral antipsychotic 
treatment when admitted for the index hospitalization).
Other outcomes of interest
PaNss and cgi-s
Seventy-two patients had a PANSS assessment documented 
at baseline and at least one additional time point during the 
12-month period. Most patients (n=65/72) had a PANSS 
assessment at or around the study endpoint. A total of 79.2% of 
these patients had a $20% improvement and a total of 47.2% 
had a $50% improvement in PANSS total score from base-
line to endpoint (Figure 2A). Overall, there was a statistically 
significant (P,0.001) and clinically relevant improvement in 
mean (SD) PANSS total score of -31.6(21.1) from baseline to 
endpoint (Figure 2B). Sixty-eight patients had a CGI-S score 
documented at baseline and at least one additional time point 
during the 12-month period. A total of 82.4% of patients were 
minimally, much, or very much improved at endpoint (defined 
as CGI-S score decrease of $2 points). There was a significant 
mean (SD) change in CGI-S score from baseline to endpoint 
of -2.5 (1.1); P,0.001 (Figure 2B). Sixty-eight patients had a 
Table 2 index hospitalization,a n (%)
Patients with an index hospitalization n=36
reason for hospitalization, n (%)
Management of episode/relapse 35 (97.2)
Other psychiatric reasons 1 (2.8)
Type of hospital, n (%)
University psychiatry department 24 (66.7)
Psychiatric/mental hospital 11 (30.6)
general/regional hospital 1 (2.8)
Duration of the index hospitalization, days (sD) 52.1 (40.6)
Time from admission date of index hospitalization 
to date of the first PP1M administration, 
days (sD)
28.8 (23.0)
Time from first PP1M administration to discharge 
date of index hospitalization, days (sD)
23.2 (24.53)
Note: aAn index hospitalization was defined as the hospital stay that started before 
the first administration of PP1M and ended after the first administration of PP1M.
Abbreviation: PP1M, once-monthly paliperidone palmitate.
Table 1 Baseline demographics, psychiatric characteristics, and 
medications
Full analysis set n=84
age, years (sD)a 24.1 (2.7)
Male, n (%) 58.0 (69.0)
Body weight, kg (sD) 79.0 (16.2)
BMi, kg/m2 (sD) 25.0 (3.5)
Age at first psychotic episode suggestive of 
schizophrenia disorder, years (sD)
23.8 (2.6)
Time between first psychotic episode suggestive of 
schizophrenia disorder and the first administration of 
PP1M, months (sD)
5.5 (3.3)
Age at first antipsychotic treatment, years (SD) 23.9 (2.6)
Psychiatric characteristics, mean (sD)
PaNss total score 95.8 (21.8)
cgi-s global score 5.0 (0.7)
PsP total score 52.1 (14.1)
gaF total score 38.7 (16.4)
Antipsychotic treatments
Time between first antipsychotic treatment and first 
administration of PP1M, months (sD)
4.8 (3.4)
First oral antipsychotic treatment prescribed to $5% of patients for the 
first psychotic episode suggestive of schizophrenia, n (%)
risperidone 31 (36.9)
Olanzapine 19 (22.6)
haloperidol 12 (14.3)
Quetiapine 6 (7.1)
Most common oral concomitant antipsychotics ($5% of patients) during 
the documentation period, n (%)
risperidone 38 (45.2)
Olanzapine 6 (7.1)
clozapine 5 (6.0)
haloperidol 5 (6.0)
Note: aall variables are reported as mean values ± SD, unless otherwise specified.
Abbreviations: BMi, body mass index; cgi-s, clinical global impression-severity; 
gaF, global assessment of Functioning; PaNss, Positive and Negative syndrome scale; 
PP1M, once-monthly paliperidone palmitate; PsP, Personal and social Performance.
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Figure 2 clinical outcomes.
Notes: (A) PaNss total score response rates at endpoint (n=72); (B) Mean change in PaNss total score and cgi-s score from baseline to endpoint. PaNss was assessed 
using the 30-item PaNss scale, which provides a total score (sum of the scores of all 30 items) and scores for three subscales, ie, the positive subscale (seven items), the 
negative subscale (seven items), and the general psychopathology subscale (16 items). each item is scored on a scale of 1 (absent) to 7 (extreme). The proportions of patients 
with each percentage improvement in the PaNss total score were summarized at each follow-up time point and at lOcF endpoint. if the scale score was not available at 
endpoint, the last available outcome was used. response rate = baseline value minus follow-up value. 
Abbreviations: cgi-s, clinical global impression-severity; lOcF, last observation carried forward; PaNss, Positive and Negative syndrome scale.
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CGI-C score documented at baseline and at least one additional 
time point during the 12-month period. At endpoint, a total 
of 70.6% of patients had a CGI-C score of #2 (were either 
much, or very much improved) at endpoint.
PsP and gaF
Forty-five patients had a PSP assessment documented at 
baseline and at least at one additional time point during the 
12-month documentation period. Most patients (n=38/45) had 
a PSP assessment at or around endpoint. The mean PSP total 
score at baseline was 52.1 (range 23–80); only 11.1% (n=5) of 
patients were rated as having good functioning or mild func-
tioning difficulties at baseline (PSP score $71). A total of 
53.3% of patients showed a significant improvement, as 
reflected by an increase in PSP total score of at least 7 points 
from baseline to endpoint (mean [SD] 11.9 [15.0] points; 
P,0.001) (Figure 3). One quarter of patients (24.4%, n=11) 
moved from a PSP score of 31–70 (ie, moderate to marked 
functional impairment) at baseline to a PSP score of mild to no 
functional impairment (PSP score $71) at endpoint. Of the 47 
patients with documented GAF scores, 72.3% (n=34) showed 
a significant improvement in GAF score as reflected by an 
increase of at least 20 points from baseline to endpoint (mean 
[SD] change 26.1 [12.3] points; P,0.001) (Figure 3).
BPRS assessments were found to be documented in only 
one patient’s medical record, and there were no SOFAS 
assessments available in any medical records.
safety
Overall, for 14.8% (n=13) of 88 patients in the safety 
analysis set, $1 ADR was reported, which was defined as 
Table 3 aDrs occurring in $2% of patients,a n (%)
Safety analysis set n=88
Weight increased 8 (9.1)
hyperprolactinemia 5 (5.7)
sluggishness 2 (2.3)
somnolence 2 (2.3)
Depression 2 (2.3)
amenorrhea 2 (2.3)
Note: asafety set.
Abbreviation: aDrs, adverse drug reactions.
an adverse event that was at least possibly causally related 
to PP1M treatment. ADRs occurring in $2% of patients are 
summarized in Table 3. Most ADRs were mild or moderate 
in severity. For three patients (3.4%), a severe ADR related 
to hyperprolactinemia was reported. Seven (8%) patients 
had an ADR that led to a dose change at the discretion of 
the treating physician. Median body weight (SD) increase 
from baseline to last PP1M administration was 1.2 (3.9) kg; 
P,0.001 (n=85).
Medical resource utilization/living-housing status/
employment and education
The most common type of outpatient consultation during 
the 12-month documentation period was consultation with 
a psychiatrist or neurologist (23.8%, n=20 patients with $1 
consultation). Only one (1.2%) patient had an emergency 
room visit. Almost all patients (97.6%, n=82) were living 
at home (alone or with family/friends) at baseline, and no 
change in living status was observed at endpoint. For those 
patients who were employed (n=19), the mean number of 
working days lost as a result of their illness or treatment 
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Figure 3 Functional outcomes: mean change in PsP and gaF total scores from baseline to endpoint.
Abbreviations: gaF, global assessment of Functioning; PsP, Personal and social Performance.
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during the last 3 months of the 12-month documentation 
period was 0.9 days (range 0–14 days), which was differ-
ent from the mean number of working days lost during the 
3 months before starting PP1M (n=13; 34.5 days [range 
0–90 days]). For the 13 patients who were students, no 
educational days were reported lost during the last 3 months 
of the documentation period (n=11), compared with a 
mean of 38.5 days lost (n=10) during the 3 months before 
starting PP1M.
Discussion
Using a pragmatic, retrospective approach, the present study 
explored the efficacy of continuous treatment with an atypi-
cal once-monthly LAT by exploring “real-world” treatment 
characteristics and outcomes in young, newly diagnosed 
adults with schizophrenia who received long-term treat-
ment with PP1M over 12 months. The retrospective and 
therefore non-interventional design enabled the evaluation 
of patients who had been diagnosed with schizophrenia 
around 5 months before treatment with PP1M and who had 
a low prior lifetime exposure to antipsychotic medication, 
in a naturalistic setting, without study-related influences on 
routine clinical practice.
The characteristics of the patient population in the present 
study reflect those of patients in naturalistic clinical settings 
in that baseline scores indicated significant levels of symp-
tom severity and functional impairment associated with an 
acute first episode of illness. Most patients in this popula-
tion maintained their dose or had a dose decrease of PP1M, 
in line with the observation that first-episode patients, in 
general, may require normal or lower doses of medication.16 
The patients in this study had likely been acutely psychotic 
for a limited period of time as indicated by the short mean 
time between first psychotic symptoms and enrollment; the 
significant clinical improvement observed in this population 
is consistent with favorable outcomes observed in young, 
first-episode patients in other studies, in which continuous 
treatment was provided by use of an atypical long-acting 
antipsychotic formulation.17 In a previous study of flexibly 
dosed PP1M in acutely ill patients with schizophrenia who 
were unsuccessfully treated with oral antipsychotics, transi-
tion to PP1M treatment resulted in significant improvement 
of symptoms as early as 1 week after the first PP1M adminis-
tration, and these improvements were further sustained over 
the following 6 months of treatment.18
In the present study, almost half of the patients achieved a 
robust treatment response (ie, $50% decrease in PANSS total 
score) by the end of the documentation period. Although there 
is no set cut-off in patients with first-episode schizophrenia,19 
it has been suggested that the most appropriate definition 
of response in schizophrenia research is a $50% improve-
ment in PANSS total score,20,21 given the generally favorable 
response to antipsychotic treatment in these patients. One 
analysis that was conducted to explore the predictive validity 
of early response in first-episode schizophrenia found that 
the best PANSS score cut-off to predict maintenance of 
response was 51.6%.22
The low rates of rehospitalization during the treatment 
period are consistent with results of a randomized controlled 
2-year study in recently diagnosed patients with schizo-
phrenia (within 1–5 years). In this study, PP1M was better 
in preventing relapse compared with physician’s choice of 
oral antipsychotics,13 an important implication given the 
evidence that relapse events may be one critical factor in 
treatment-emergent refractoriness.3 Compared with multi-
episode patients, those with first-episode schizophrenia are 
more likely to achieve remission, as they are more likely to 
respond favorably to antipsychotic treatment.17,23
The safety results in the present study suggest that the 
treatment for those patients receiving PP1M for 12 months 
or longer was well tolerated and ADRs were consistent with 
the known safety profile of PP1M.13,18,24,25 This is noteworthy 
given that patients with newly diagnosed schizophrenia may 
be particularly susceptible to antipsychotic side effects, such 
as weight gain, metabolic abnormalities, and extrapyramidal 
symptom (EPS) side effects.26,27 The mean changes in body 
weight and body mass index observed in the current study 
did not differ from those changes observed in other studies 
with PP1M in patients with more chronic schizophrenia.24,28 
The incidence of EPS-related ADRs and the use of anti-
cholinergic medication was low; these results are in line 
with observations that young patients in remission received 
lower doses of a long-acting antipsychotic and had fewer 
EPS side effects.17
limitations
This was a retrospective chart review, designed to explore 
treatment outcomes with PP1M in newly diagnosed patients 
with schizophrenia over a long-term period (at least 12 months) 
by use of efficacy measures as they were routinely documented 
in patients’ medical records. Sites were eligible for participa-
tion if standard efficacy measures were documented at least at 
the beginning of treatment with PP1M and at the end of the 
observation period (at least 12 months later). Furthermore, 
sites were requested to capture these measures if available 
from the medical records at any time point in between, but 
it was expected that such measures may not be frequently 
assessed in routine clinical settings, or that the frequency of 
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such assessments may vary considerably between sites and 
patients. Although the inclusion of patients with more than 
two documented assessments may have further strengthened 
the results, it would have required a highly complex selection 
process and considerable efforts to select sites and patients’ 
records with similar and/or comparable assessment dates. 
These criteria may have biased the study-site selection. 
Inclusion criteria required patients to have been receiving 
PP1M for at least 12 months, thereby selecting a group that 
continued and responded well on PP1M. Therefore, the 
present results cannot be generalized to patients who were 
treated with PP1M for a shorter or longer period of time or 
a broader schizophrenia population, because of the specific 
patient group assessed (young, adult, recently diagnosed 
patients with schizophrenia who had been treated with PP1M 
for at least 12 months). The objective of this pragmatic and 
naturalistic study was not to compare different treatments; 
therefore, no active treatment control group was included 
in the design. Nevertheless, this limits the generalizability 
of the conclusions drawn. However, the outcomes of this 
study can be indirectly compared with outcomes from other 
similar open-label studies conducted in similar populations 
of patients with schizophrenia.17
Conclusion
The present study aimed to address the paucity of naturalistic 
data in young patients with schizophrenia treated with an 
atypical LAT at an early stage of the illness and over a longer 
period of time. In this study, continuous treatment with PP1M 
over 12 months was associated with statistically significant 
and clinically meaningful improvements in psychotic symp-
toms, disease severity, and functional outcomes in patients 
with schizophrenia. More importantly, the rate of hospital-
ization over the 12 months of treatment was low, which is 
consistent with evidence demonstrating that treatment of 
schizophrenia with LAT can improve relapse rates.6,8,12–14 The 
importance of these findings rests in the clinical imperative 
of managing first-episode patients to prevent further relapses 
and to minimize the burden and distress that these relapses 
may have in derailing hard-won progress in psychosocial 
recovery; and in reducing both the risk of persistent psychosis 
after each new episode and the added economic burden of 
treating relapse.7 Results of this study suggest that PP1M is 
efficacious and well tolerated when used as an early option 
in treating schizophrenia. Continuous antipsychotic treatment 
during the early years of the disease may be critical, as this is 
when the illness is at its most aggressive, and when relapses 
and illness progression are most likely to occur.29,30
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